Section 232 Pharmaceutical Tariffs and Drawback

Primary source: Original White House pharmaceutical proclamation, April 2, 2026. The same proclamation is published as Federal Register Proclamation 11020.

Executive snapshot

Chapter 99 duty-rate matrix

The headings are mutually exclusive. If more than one pharmaceutical Section 232 rate could apply, the official annex structure points companies toward the applicable lower treatment, but importers should verify the current HTSUS note and any later CBP guidance before filing.

Key dates

Why this matters for drawback

The proclamation states that drawback is available for duties imposed under the pharmaceutical Section 232 action. That is different from many importer assumptions about Section 232, because some Section 232 programs prohibit drawback or limit it to narrow manufacturing situations.

For pharma, the practical question is not only "is drawback available?" The real question is which drawback path the facts support.

Classification workflow

1. Confirm the ordinary Chapter 29 or Chapter 30 HTSUS subheading.
2. Check whether the subheading appears in U.S. Note 40(c).
3. Determine whether the article is a patented pharmaceutical article, associated ingredient, active pharmaceutical ingredient, or key starting material.
4. Separate patented products from generics and biosimilars.
5. Identify whether the article is a specialty product under heading 9903.04.66.
6. Determine country of origin and whether country-specific treatment applies.
7. Check whether the importer or manufacturer has Annex III, onshoring-plan, or MFN pricing agreement status.
8. Determine whether U.S.-origin active ingredient dosage-form treatment applies.
9. Apply only one of the 9903.04.60 through 9903.04.69 headings, then preserve the decision evidence with the entry record.

FTZ and stacking notes

Covered goods admitted into a foreign-trade zone after the effective date generally must be admitted in privileged foreign status unless they are eligible for domestic status. That matters because the Chapter 99 rate can follow the merchandise when it later enters U.S. commerce.

The pharmaceutical Section 232 duties are in addition to applicable antidumping, countervailing, and other duties and charges. They also sit on top of ordinary entry data, classification, origin, and valuation controls. A drawback model should keep the pharmaceutical Section 232 duty separate from other duty buckets so finance teams can forecast recovery and so reviewers can audit the calculation line by line.

Covered HTSUS subheadings

U.S. Note 40(c) lists 131 Chapter 29 and Chapter 30 HTSUS provisions. A covered HTSUS subheading is only the starting point. Product status still matters.

Data Pax would request

For a pharmaceutical Section 232 drawback review, Pax would typically request:

• ACE entry summaries and broker packets with Chapter 1 through 97 and Chapter 99 classification.
• Product master data, patent status, generic or biosimilar status, and pharmaceutical article determinations.
• Active ingredient and key starting material records, including origin and dosage-form evidence.
• Annex III, onshoring-plan, MFN pricing agreement, or specialty-product support where relevant.
• Import invoices, purchase orders, country-of-origin support, and landed-cost records.
• Export records, destruction records, or manufacturing records depending on the target provision.
• Lot, batch, serial, bill of material, inventory movement, quality, and deviation records.
• Reviewer approvals, evidence exceptions, calculation logs, and claim-right documentation.

Pax angle for pharma

Pharmaceutical companies already manage dense regulatory and quality records, but those records rarely sit in the same system as customs entries, broker files, export evidence, and drawback calculations. Pax connects the tariff classification layer to the operational evidence layer so trade compliance, finance, supply chain, quality, and tax teams can see which import lines are exposed, which duty buckets are recoverable, which provision is strongest, and which records are missing before filing.

Related resources

• Section 232 drawback matrix
• Duty drawback data requirements
• Manufacturing drawback
• Rejected merchandise drawback

Sources

• Original White House pharmaceutical proclamation, April 2, 2026
• White House pharmaceutical annexes
• Original Federal Register publication, Proclamation 11020
• Federal Register, pharmaceutical onshoring agreement procedures
• 19 U.S.C. 1313, drawback and refunds

Last verified: June 1, 2026.